Inventiva Strengthens Board With Renée Aguiar-Lucander, Former Calliditas CEO

Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH), has appointed Renée Aguiar-Lucander to its Board of Directors. Aguiar-Lucander brings extensive leadership experience in biotech, with a strong record of strategic growth and commercialization.

Renée Aguiar-Lucander expressed, saying, “I’m honored to have the opportunity to join Inventiva’s Board. With the NATiV3 Phase 3 trial fully enrolled, I look forward to working with the team to potentially bring lanifibranor to patients with MASH.”

She currently serves as Chief Executive Officer of Hansa Biopharma, a role she assumed in April 2025. Previously, as CEO of Calliditas Therapeutics, she led the company’s transformation into a Nasdaq-listed commercial-stage leader in rare diseases. Under her leadership, Calliditas secured the first FDA approval for a treatment in IgA nephropathy (TARPEYO®), launched the drug in the U.S., and completed a $1.1 billion acquisition by Asahi Kasei in 2024.

Mark Pruzanski, Chairman of Inventiva, commented,  “We are thrilled to welcome Renée to the Board at this pivotal moment in Inventiva’s journey. Her exceptional track record in our industry speaks for itself and will be key as we enter the final stages of clinical development for lanifibranor and prepare for its potential approval and launch.”

Aguiar-Lucander additionally has experience in senior positions in life sciences investment and finance, having worked as Partner and COO at Omega Fund Management and also Managing Director at an international investment bank. She has earned an MBA, INSEAD and a BA Finance from, Stockholm School of Economics. Her recruitment is hoped to enhance the strategic orientations and governance of Inventiva as it pursues its MASH pipeline.